Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANKU-Breast04: BL-B01D1 + PD-1 antibody versus nab-paclitaxel + PD-1 antibody in first-line PD-L1-positive advanced triple-negative breast cancer
CTR20262666Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan, paclitaxel, PD-1 Monoclonal Antibody in triple-negative breast cancer (TNBC), sponsored by Biokin Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
izalontamab brengitecanpaclitaxelPD-1 Monoclonal Antibody
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20262666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262666.